Osmind

10/14/2026

Some people have tried three antidepressants. Five. Seven. And still haven’t found meaningful relief.

That’s treatment-resistant depression (TRD), and an estimated 4 million Americans are living with it. Today, for the first time, it has its own awareness day.

We’re proud to join Compass Pathways and leading advocacy organizations in marking .

Across the Osmind community, we see what’s possible when people with TRD reach clinicians who specialize in interventional treatment. Earlier this year, we helped define “interventional psychiatry” in Nature Mental Health, because shared language is how a field grows and how more patients find their way to it.

Awareness is the first step. Earlier recognition is the next. Our mission is to help clinicians bring evidence-based treatments to the patients who need them most.

If you or someone you love is living with TRD, you are not alone.

10/08/2026

What breaks when interventional psychiatry practices scale? On a recent webinar, the co-founders of Rise4 walked through how to find and close bottlenecks in your practice.

In part 2 of our recap, we cover what happens to your patients between their first inquiry and their last session.

Rise4 reported they commonly see 3-8% leads reach a booked evaluation at clinics running intake in-house. On 1,000 inquiries, that's 30 to 40 evaluations versus roughly 80.

Most practices respond to the low end by buying more leads. But adding demand to a leaky operation raises the cost of every gap.

The guide walks seven stages of your practice funnel with what to measure at each:
•Response time and who owns intake
•Pre-screening that keeps intake focused on qualified patients
•Prior auth: tracking your own turnaround and the payer’s to pinpoint slowdowns
•Treatment completion, and what you should do after

William Sauvé, MD traced most early stops in his own practice to surprise bills or patients who never understood why finishing treatment mattered. Both are communication problems.

Prior authorizations are also often where growth breaks first. If one person is barely submitting two authorizations a week at one site, a second and third location caps how many patients the whole practice can start.

Featuring Rise4 Co-founders, Justin Gammill and Jake Buchanan

Get the guide in the comments.

10/01/2026

Amast Health built a Spravato practice from scratch, but operations consumed precious time.

"The things that we didn't have a plan for yet were the things that Osmind was gonna take care of."

Compliance, claims, payer contracts, and the revenue cycle required for scaling with insurance in interventional psychiatry.

“ Osmind had already really positioned themselves as the EMR for interventional practices. I knew they really built out their system very well.“

Full story on Amast Health building for psychiatry's next era at the link in comments.

09/30/2026

For two years, Sahab Yaqubi, M.D. ran his EHR in one system and his billing in another, connected by a clearinghouse and a shared folder.

"The problem was that there were several systems. Here it's all one."
PathWave Psychiatry now runs more than 220 encounters a month with Dr. Yaqubi as its only prescribing clinician, offering Spravato, TMS, and medication management to patients with treatment-resistant depression and anxiety.

On Osmind 360, the practice collects from payers in about 26 days, ahead of the 35-day industry norm.

For the first time, he can see his own revenue cycle numbers.

“If you want to do simple medication management, without depending on Spravato prior authorizations, maybe other options can be helpful. But for an interventional psychiatry practice like ours, having the EHR, billing, and authorization workflows integrated in one platform has been a significant improvement”

Solo prescriber Sahab Yaqubi, MD, runs 220+ monthly Spravato and TMS encounters. PathWave moved EHR, billing, and prior auths onto one Osmind platform and now collects in 26 days.

09/23/2026

What breaks when your interventional psychiatry practice grows faster than the systems supporting it?

More inquiries can mean more missed follow-ups. More referrals can leave teams chasing the next step. More capacity can sit unused while the same bottlenecks keep people from starting treatment.

We ran a session with Rise4 to help you find and close those bottlenecks, and wrote-up a practical guide (linked in comments) on non-obvious ways to find more patients in your own panel.

In a typical 300 to 400 patient panel, at least 50 to 60 patients would likely clear prior authorization for TMS or esketamine right now.

Most practices go looking for new demand before they look at that.
This pt. 1 of this guide, Jake Buchanan, Justin Gammill, and our own William Sauvé, MD cover:

•How to find patients in your own panel
•A five-part referral engine
•An exit folder idea you can take with you

Before you spend money on marketing or ads, start with shoring up your systems and look to your existing patient panel.

Full guide in comments 👇

09/22/2026

We’re honored to have TIME recognize Osmind as one of the World's Top Health Tech Companies of 2026!

This is the second year we made this list. What makes our mission worthwhile is the people we serve—psychiatrists and nurse practioners delivering novel treatments for depression, researchers advancing psychedelic medicine, practices scaling operations with our platform.

2026 and 2027 are breakthrough years for fast-tracking psychedelic approvals. As we sail into uncharted waters, we're working hard to ensure practices can deliver them safely and profitably when the time comes.
Thank you TIME and thank you to all the mental health innovators that inspire us every day!

09/18/2026

Two psychiatrists built a Spravato (esketamine) practice designed to end.
"At the end of the day, it's not us or the medication changing people's lives. It's people changing their own lives." — Michael Dinh, MD

Amast Health runs Spravato as a structured 10-week course rather than open-ended treatment, with psychotherapy bracketing every session so the medication opens a window instead of becoming the whole plan.

Since moving onto Osmind, the San Francisco practice is collecting 98.7% of what it's owed from payers, against a behavioral health average closer to 85-90%, and getting paid in about 10 days, roughly three-times faster than the 30-to-40-day industry standard.

"Part of the reason we chose Osmind is that we were envisioning not just the first year or the second year. We were choosing a partner we could grow with as more psychedelic medications become FDA approved," Jack Buchanan, MD, PhD says.

These two founders expect the landscape to get more complex, in a good way, as more options become available to patients. Should psilocybin or M**A reach approval, Amast Health wants the clinic, staff, training, and clinical model ready on their side, and the contracts, revenue structures, and regulatory work ready on Osmind's.

09/17/2026

In 2020, our co-founders, Lucia Huang and Jimmy Qian started knocking on clinic doors because they’d seen what ketamine could do for patients who'd run out of treatment options, and how hard it was for independent practices to actually offer it. That's why they built Osmind.

Today, Osmind powers the largest network of interventional psychiatry practices in the country, and we're proud to sponsor American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3)'s Mastering the Essentials again this year.

Whether you're launching your first ketamine program or scaling into Spravato and TMS, we're here to help you automate admin and capture more revenue, so you focus on what matters. Good medicine can and should be good business.

Find our team at our table in Denver, September 25–27. We've got an offer just for Mastering the Essentials attendees.

09/14/2026

You know the patient who arrives with a coping strategy that was adaptive at twenty-four and calcified into a constraint at thirty-four?

Your psychiatry practice can do the same thing.

The systems that got you from zero to one work fine at low volume. They work because someone knows the workarounds.

Then you add a clinician, a treatment room, and another modality.
Growth starts feeling like overhead, because you’re likely running your practice on tools that constrain over time.

If your net collection rate is under 95%, revenue is leaking somewhere for care you already delivered. We've seen gaps run well into six figures a year, on work already done.

We wrote up the six places that gap costs practices money, and the four-minute test that tells you whether it's costing you (link in comments)👇

09/03/2026

“Interventional psychiatry” has been part of the field’s vocabulary for years, but there has never been a formal definition of what it really means.

Our new paper published in Nature Mental Health, “Defining interventional psychiatry: A framework for professional identity and practice evolution,” offers a clear framework for what the field is, what distinguishes it, and how it should evolve.

Nine leaders spanning clinical practice, research, academia, and industry came together to develop it: William Sauvé, MD, Thomas Insel MD, Brittany Albright MD, MPH, DABOM, Martha B. Koo, M.D., LFAPA, FASAM, FCTMSS, Rob Berman, Stephen M. Stahl, MD, PhD, DSc(Hon), DMedSci (Hon, Cambridge), Husseini Manji, MD, FRCPC, Roger McIntyre, and Jimmy Qian.

Their central argument is simple: interventional psychiatry is not defined by a list of tools or procedures. It is defined by the integration of psychiatric judgment with the direct delivery or oversight of specialized treatments, including responsibility for patient selection, real-time management, and longitudinal care.

The paper also proposes a risk-based framework for training and credentialing, with standards matched to procedural complexity and safety rather than a one-size-fits-all certification model.

Osmind is proud to support more than 1,000 interventional psychiatry practices nationwide. A clearer definition can help establish the field’s boundaries, strengthen its professional identity, and guide the next chapter of training, practice, and patient care.